This startup develops a synthetic biology platform that integrates AI and biological engineering to design and manufacture new biomaterials and drugs. Their technology enables industries to create essential products using more sustainable and efficient production methods.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional manufacturing processes for biomaterials and pharmaceuticals often rely on unsustainable fossil fuels and inefficient production methods. The development of new drugs and therapies is also hampered by ineffective methods and unwanted side effects.
Solution
Alstonia Bio is developing a synthetic biology platform that leverages AI and biological engineering to design and manufacture novel biomaterials and drugs. The company's bio-foundry enables the creation of sustainable and efficient alternatives to traditional materials and production processes. By combining AI-driven design with synthetic biology, Alstonia Bio aims to create new drugs and therapies that are more effective and have fewer side effects. The platform facilitates the engineering of biological systems for the production of biofuels, biomaterials, and pharmaceuticals.
Target Audience
Alstonia Bio's primary customers include companies in the healthcare, agriculture, manufacturing, and energy sectors seeking sustainable and efficient production methods for biomaterials, pharmaceuticals, and novel therapies.
Features
- AI-driven design of biological systems for targeted functionalities
- Development of new biofuels and biomaterials that are more sustainable and efficient than traditional fossil fuels and plastics
- Engineering of bacteria to produce ethanol from cellulosic biomass, such as wood and agricultural waste
- Engineering of viruses to deliver cancer-killing genes to tumor cells
- Development of new antibodies that are more specific to cancer cells
- Antibody engineering to have multiple binding domains, cross the blood-brain barrier, or deliver drugs or other therapeutic molecules